Br J Nutr 122:625638
Quick Comparison Feature CagriSema Retatrutide Development owner Novo Nordisk Eli Lilly Core strategy Combination therapy Single-molecule multi-agonist Pathways Amylin + GLP-1 GIP + GLP-1 + glucagon Main components Cagrilintide + semaglutide Retatrutide (LY3437943) 2026 status Phase 3 / regulatory-watch candidate Phase 3 TRIUMPH program Best-fit research question Can amylin extend GLP-1 results
Bondeson DP, Mares A, Smith IED, Ko E, Campos S, Miah AH, et al
This beauty supplement is crafted to support a radiant complexion and youthful skin health as part of your balanced daily routine
Where results show up at all, they tend to appear gradually over weeks, not days
In cosmetic formulation, it functions as a potent skin brightening active by inhibiting tyrosinase, the enzyme that drives melanin synthesis, and redirecting melanogenesis from the darker eumelanin pathway to the lighter phaeomelanin pathway